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properties for only 8 have been compared in 4 different pub-
lished studies. A common comparator in all four studies has been
the Medical Outcomes Survey Short Form (SF-36). Responsive-
ness to change and patient preferences regarding the question-
naires have been compared less frequently. Overall, the Multiple
Sclerosis Impact Scale (MSIS-29) has been shown to perform
better over a range of psychometric properties compared to the
commonly used MSQOL and the Functional Assessment in MS
(FAMS). CONCLUSIONS: MSIS-29 appears to be a psychome-
trically sound measure of QOL in MS. However, owing to the
paucity of psychometric comparisons in the MS literature,
further rigorous head-to-head comparisons of newer as well as
existing questionnaires with MSIS-29 are warranted. Such results
can guide researchers in selecting an appropriate measure for use
in clinical trials as well as routine clinical practice.
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OBJECTIVES: Understanding the real-world effectiveness of
triptans in migraine, a trial was conducted using patient-reported
outcomes to evaluate the beneﬁt of triptan therapy before and
after switching to eletriptan 40mg. METHODS: Physicians
enrolled migraineurs into an open-label treatment-satisfaction
study using web-based data collection technology. Patients’
demographic information, migraine experience, utilization of
health care resources and level of satisfaction with prior migraine
therapy (both prescription and over-the-counter treatments)
were evaluated separately for headache pain relief, speed of pain
relief and ability to return to daily activities. Patients were then
switched to eletripan 40mg and their level of satisfaction across
each outcome domain was measured for three migraine attacks.
RESULTS: Of the 2778 patients enrolled (87.1% female; mean
age, 37.4 years; 83.6% employed; averaged 5.5 attacks per
month lasting a mean duration of 11 hours; 49.9% high health
care utilizers [≥1 headache-related outpatient and/or emergency
room visit per month]), 2303 (82.9%) treated at least one
migraine attack with eletriptan 40mg. Patient-reported satisfac-
tion (4 or 5 on a 5-point scale) with eletriptan 40mg was 68.8%,
57.2% and 62.8% for headache pain relief, speed of pain relief
and ability to return to daily activities, respectively, and was sig-
niﬁcantly greater when compared with satisfaction with prior
therapy (triptan and non-triptan): 29.8%, 22.1% and 21.7%,
respectively (p < 0.001). Seventy percent of high health care uti-
lizers achieved satisfactory-to-completely-satisfactory pain relief
on eletriptan 40mg. Employed patients were signiﬁcantly more
satisﬁed (64.2%) than unemployed patients (56%) with eletrip-
tan 40mg (p < 0.01). CONCLUSION: Increased level of patient
satisfaction on eletriptan when compared with prior therapy
indicates a signiﬁcant unmet need for optimized treatment of
acute migraine in this patient population. Further research is
required to determine whether increased satisfaction is associ-
ated with decreased health care utilization. Such real-world effec-
tiveness data might be useful in formulary decision making and
health care beneﬁt design.
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OBJECTIVES: Determine impact of a worksite disease manage-
ment program (DMP) on work productivity loss among employ-
ees with migraines. METHODS: A total of 712 health risk
assessment questionnaires were distributed to employees of a
medical group (64% response rate), with 180 identiﬁed as
migraineurs using IHS criteria from respondent self-report.
Migraineurs were given a DMP which included: 1) tailored
behavioral print material; 2) headache diary; 3) access to work-
site presentations (“Lunch & Learns”) by a physician on trig-
gers, diagnosis and treatment options, Q&A, and instruction on
completion of the MIDAS (Migraine Disability Assessment); 4)
headache tipsheets and suggestions for web-based resources; and
5) access to worksite physicians for same-day treatment. A
follow-up questionnaire distributed 12 months post-launch
revealed no nonresponse bias between respondents (n = 73) and
nonrespondents (n = 107). The primary dependent measure of
the evaluation was work productivity loss (WPL), which com-
bined absenteeism (full and partial days missed due to headache)
and presenteeism (days worked with headache and self-reported
productivity) during the past four weeks. RESULTS: Only 52%
of migraineurs recalled reading the provided tailored educational
print materials on managing their headaches, 28% reported
attending Lunch & Learn sessions, and 7–13% used other
program components. Mean lost productivity dropped only
slightly from baseline to follow-up (8.3 v 7.3 hours, NS).
However, subgroup analyses revealed the program was effective
in signiﬁcantly (p < 0.05) reducing WPL for employees who 1)
increased their level of conﬁdence to control their headaches
after program exposure (6.7 v. 2.3 hours), and 2) sought medical
care for headaches and used migraine prescription medications
(13.4 v. 4.1 hours). CONCLUSIONS: Overall, the DMP failed
to reduce productivity loss among employees with migraines;
however promising ﬁndings were observed for selected groups.
Future programs need to identify effective strategies to improve
self-conﬁdence in headache management and to engage more
migraineurs in seeking medication attention.
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OBJECTIVES: The objective was to determine whether there
was a signiﬁcant association between Body Mass Index scale
(underweight, normal, overweight, moderate obesity, severe
obesity, and very severe obesity) and national medical expendi-
tures (dependent variable) for persons, 18 to 65 years of age,
controlling for demographics of gender, race, marital status, and
education. METHODS: The database used was the Medical
Expenditure Panel Survey (MEPS) for the year 2002. A two-part
model was used to analyze the association between obesity and
health care expenditures. The ﬁrst part was a logistic regression
or binary model, in which expenditures were either existent or
non-existent. This model was adjusted by the demographic vari-
ables of gender, age, race, marital status, and education. The
second part modelled the relationship between expenditure and
BMI. This model was also adjusted by the study demographics.
Park’s test was performed to determine which distribution family
ﬁt the data. In order to accomplish this a General Linear Model
(GLM) framework was used. RESULTS: Approximately 64% of
the sample was overweight or obese. The rest were normal or
underweight. According to the logistic regression, Body Mass
